---
title: "How family history differentiates monogenic from polygenic ALS: simulation study using APECS"
id: "medrxiv-5-the-value-of-a-family-history-to-distinguish-monogenic-from-polygenic"
canonical_url: "https://medichelpline.com/clinical-feed/medrxiv-5-the-value-of-a-family-history-to-distinguish-monogenic-from-polygenic"
content_type: "clinical_feed_article"
specialty: "Neurology"
source_name: "medRxiv (Clinical Preprints)"
source_url: "https://www.medrxiv.org/content/10.64898/2026.09.16.26362994v1?rss=1"
published_at: "2026-09-22T12:00:00.000Z"
evidence_level: "Verified Feed"
license: "CC-BY-NC-4.0 / Informational Use"
---
# How family history differentiates monogenic from polygenic ALS: simulation study using APECS
## Provenance & Clinical Metadata
- **Canonical URL:** https://medichelpline.com/clinical-feed/medrxiv-5-the-value-of-a-family-history-to-distinguish-monogenic-from-polygenic
- **Specialty:** [Neurology](https://medichelpline.com/clinical-feed/neurology.md)
- **Primary Source:** medRxiv (Clinical Preprints)
- **Source URL:** [Original Journal Publication](https://www.medrxiv.org/content/10.64898/2026.09.16.26362994v1?rss=1)
- **Published At:** 2026-09-22T12:00:00.000Z
- **Evidence Rating:** Verified Feed
## Executive GIST (TL;DR)
- Familial recurrence of **amyotrophic lateral sclerosis (ALS)** or **frontotemporal dementia (FTD)** is conventionally used to infer Mendelian, monogenic inheritance and guide genetic testing and counselling. - Polygenic risk and reduced-penetrance pathogenic variants can both produce familial clustering or apparently sporadic presentations, complicating interpretation of pedigree-based criteria. - The authors developed the APECS simulator, a large-scale pedigree simulator that integrates historical demographic parameters and unifies monogenic and polygenic disease models to study genetic architecture in ALS. - They simulated 1,000,000 three-generation pedigrees, generating 55.3 million individuals and identifying 5,431 ALS-affected index patients; 16.4% of these were modelled as monogenic. - The proposed 'definite fALS' criterion (≥2 relatives with ALS within two degrees) showed 31.1% sensitivity for detecting monogenic index patients and misclassified 10.0% of cases labeled 'fALS' as monogenic (false positives reported as percentage of fALS?). - Including relatives with definite **FTD** improved sensitivity of the 'definite fALS' criterion to 43.3%; expanding to any type of dementia increased the false positive rate to 35.9% and reduced accuracy. - Simulations estimated a 5.3% phenocopy rate among monogenic index patients, defined as relatives with polygenic ALS or an unrelated pathogenic allele in kin up to third degree. - Among monogenic index patients who appeared sporadic, 83.1% had distant relatives with ALS/FTD up to the fifth degree, indicating value in detecting distant relatedness. - The authors conclude that a **family history** has limited accuracy for inferring underlying genetic architecture in ALS; reliance on traditional familial ALS (fALS) criteria risks both missed opportunities for genetic testing and false reassurance/alarms. - Recommendations from the study: routine genetic testing regardless of family history and systematic approaches to detect distant relatedness may improve identification of known and novel genetic causes in ALS. - Data and code for APECS are publicly available on GitHub; a web-based calculator for monogenic probability is provided by the authors. - Competing interests and funding: one author reports sponsored research agreements with several companies; funders include the ALS Foundation Netherlands and the European Research Council.
## Clinical Analysis & Structured Key Points
[](https://www.medrxiv.org/cdn-cgi/content?id=wLw8vhL0QyhDzPSO.GLGKctWM0e9MVxEFtGVx_CGta4-1790096010.4155889-1.2.1.1-3s31AQzcZ2Wr9UELugK6fWuxUZB1otOh9PFBZiOvMuW8a57d_ajmWI32ZQxJWoL0) [Skip to main content](https://www.medrxiv.org/content/10.64898/2026.09.16.26362994v1?rss=1#main-content) [![medRxiv](https://www.medrxiv.org/sites/default/files/medrxiv_inner_logo.png)](https://www.medrxiv.org/) * [Home](https://www.medrxiv.org/) * [Submit](https://www.medrxiv.org/submit-a-manuscript) * [FAQ](https://www.medrxiv.org/about/FAQ) * [Blog](https://connect.medrxiv.org/news/) * [ALERTS / RSS](https://www.medrxiv.org/content/alertsrss) * [Resources](https://connect.medrxiv.org/resources/) * [About](https://www.medrxiv.org/content/about-medrxiv) Search for this keyword [Advanced Search](https://www.medrxiv.org/search) Follow this preprint # The value of a family history to distinguish monogenic from polygenic amyotrophic lateral sclerosis [ View ORCID Profile](http://orcid.org/0000-0003-0478-0836)Paul Beele, [ View ORCID Profile](http://orcid.org/0000-0001-5572-9657)Jan Veldink, [ View ORCID Profile](http://orcid.org/0000-0002-5860-1533)Wouter van Rheenen doi: https://doi.org/10.64898/2026.09.16.26362994 [This article is a preprint and has not been certified by peer review [](https://www.medrxiv.org/about/FAQ#unrefereed)[what does this mean?](https://www.medrxiv.org/about/FAQ#unrefereed)]. It reports new medical research that has yet to be evaluated and so should _not_ be used to guide clinical practice. Paul Beele Department of Neurology, UMC Utrecht Brain Center, University Medical Center Utrecht, Utrecht University, Universiteitsweg 100, Utrecht 3584 CG, The Netherlands * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Paul%2BBeele%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Beele%20P&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3APaul%2BBeele%2B) * [ORCID record for Paul Beele](http://orcid.org/0000-0003-0478-0836 "Open in new tab") Jan Veldink Department of Neurology, UMC Utrecht Brain Center, University Medical Center Utrecht, Utrecht University, Universiteitsweg 100, Utrecht 3584 CG, The Netherlands * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Jan%2BVeldink%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Veldink%20J&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3AJan%2BVeldink%2B) * [ORCID record for Jan Veldink](http://orcid.org/0000-0001-5572-9657 "Open in new tab") Wouter van Rheenen Department of Neurology, UMC Utrecht Brain Center, University Medical Center Utrecht, Utrecht University, Universiteitsweg 100, Utrecht 3584 CG, The Netherlands * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Wouter%2Bvan%2BRheenen%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=van%20Rheenen%20W&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3AWouter%2Bvan%2BRheenen%2B) * [ORCID record for Wouter van Rheenen](http://orcid.org/0000-0002-5860-1533 "Open in new tab") * For correspondence: w.vanrheenen-2@umcutrecht.nl * [Abstract](https://www.medrxiv.org/content/10.64898/2026.09.16.26362994v1)[](https://www.medrxiv.org/panels_ajax_tab/biorxiv_tab_art/node:1305268/1) * [Info/History](https://www.medrxiv.org/content/10.64898/2026.09.16.26362994v1.article-info)[](https://www.medrxiv.org/panels_ajax_tab/biorxiv_tab_info/node:1305268/1) * [Metrics](https://www.medrxiv.org/content/10.64898/2026.09.16.26362994v1.article-metrics)[](https://www.medrxiv.org/panels_ajax_tab/article_tab_metrics/node:1305268/1) * [Supplementary material](https://www.medrxiv.org/content/10.64898/2026.09.16.26362994v1.supplementary-material)[](https://www.medrxiv.org/panels_ajax_tab/biorxiv_tab_data/node:1305268/1) * [Data/Code](https://www.medrxiv.org/content/10.64898/2026.09.16.26362994v1.external-links)[](https://www.medrxiv.org/panels_ajax_tab/article_tab_data_code/node:1305268/1) * [ Preview PDF](https://www.medrxiv.org/content/10.64898/2026.09.16.26362994v1.full.pdf+html)[](https://www.medrxiv.org/panels_ajax_tab/biorxiv_tab_pdf/node:1305268/1) ![Loading](https://www.medrxiv.org/sites/all/modules/contrib/panels_ajax_tab/images/loading.gif) ## Abstract Familial recurrence of amyotrophic lateral sclerosis (ALS) or frontotemporal dementia (FTD) is the clinical cornerstone for assuming Mendelian, monogenic inheritance which informs genetic testing, counselling and gene-discovery strategies in standard practice. Polygenic inheritance can lead to familial clustering of ALS, while pathogenic variants with reduced penetrance may present sporadically in small, modern-day pedigrees. As both rare genetic variants and polygenic disease contribute to the occurrence of ALS, the accuracy of a positive family history to predict the underlying genetic architecture remains unknown. Using growing knowledge of the genetic architecture of ALS, we designed the APECS simulator: a large-scale pedigree simulator using historical demographic parameters, unifying frameworks for monogenic and polygenic disease models. We simulated 1,000,000 three-generation pedigrees and modelled ALS, FTD, and other dementias under both inheritance models. For index patients with ALS, we examined the performance of proposed familial ALS (fALS) definitions to predict the underlying genetic architecture. Simulation results were benchmarked against real-world population estimates, over a wide range of demographic and genetic parameters. We assessed the phenocopy rate for monogenic index patients, defined as relatives with polygenic ALS or a pathogenic allele from a different ancestor. Finally, we illustrated the value of distant relatedness among apparently sporadic, but monogenic ALS patients. Simulations generated 55.3 million individuals, yielding 5,431 ALS-affected index patients (16.4% monogenic). The proposed criterion for 'definite fALS' (2 or more relatives with ALS among relatives within two degrees) had a 31.1% sensitivity, while falsely classifying 10.0% of 'fALS' as monogenic. The sensitivity of 'definite fALS' was improved to 43.3% when also considering relatives with FTD. Considering any type of dementia raised the false positive rate to 35.9%. In total, 5.3% of monogenic index patients had a phenocopy with ALS in relatives up to the third degree. Of seemingly sporadic monogenic index patients, 83.1% had distant relatives with ALS/FTD up to the fifth degree. A family history provides limited accuracy for inferring genetic architecture in ALS. Considering unspecified dementias in the family history reduces this accuracy, while adding definite FTD improves accuracy. Relying on traditional fALS criteria risks both missing cases for genetic testing and treatments, and falsely alarming families with polygenic ALS. Given the limited value of a family history and risk of phenocopies, routine genetic testing regardless of family history and systematic approaches for detecting distant relatedness will help to find known and novel genetic causes in ALS. ### Competing Interest Statement JHV reports to have sponsored research agreements with Biogen, Eli Lilly, Trace and AstraZeneca. ### Author Declarations I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained. Yes I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals. Yes I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance). Yes I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable. Yes ## Data Availability The data and code used for this study are available from Github: https://github.com/wvanrheenen/APECS. ## Funder Information Declared ALS Foundation Netherlands European Research Council, Grant agreement n° 772376 – EScORIAL Copyright The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission. bioRxiv and medRxiv thank the following for their generous financial support: > The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, The University of Edinburgh, University of Washington, and Vrije Universiteit Amsterdam. [Donate to openRxiv ](https://www.zeffy.com/en-US/donation-form/donate-to-make-a-difference-10981) [ Back to top](https://www.medrxiv.org/content/10.64898/2026.09.16.26362994v1?rss=1#page) [ Previous](https://www.medrxiv.org/content/10.64898/2026.09.16.26363194v1 "Immunogenicity and vaccine effectiveness of COVID-19 vaccines in people on immunosuppressive therapies")[Next ](https://www.medrxiv.org/content/10.64898/2026.09.20.26363510v1 "Within-Year PM2.5 Exposure Structure Provides Mortality-Predictive Information Beyond the Annual Mean") Posted September 22, 2026. [ Download PDF](https://www.medrxiv.org/content/10.64898/2026.09.16.26362994v1.full.pdf) Print/Save Options [Download PDF](https://www.medrxiv.org/content/medrxiv/early/2026/09/22/2026.09.16.26362994.full.pdf)Full Text & In-line FiguresXML [More Info](https://www.medrxiv.org/about/FAQ#PrintOptions "More Information on Print/Save Options") [ Author Declarations](https://www.medrxiv.org/content/10.64898/2026.09.16.26362994v1#p-5) [Supplementary Material ](https://www.medrxiv.org/content/10.64898/2026.09.16.26362994v1.supplementary-material) [ Data/Code](https://www.medrxiv.org/content/early/2026/09/22/2026.09.16.26362994.external-links) [ Email](https://www.medrxiv.org/ "Email this Article") [ Share](https://www.medrxiv.org/) The value of a family history to distinguish monogenic from polygenic amyotrophic lateral sclerosis Paul Beele, Jan Veldink, Wouter van Rheenen medRxiv 2026.09.16.26362994; doi: https://doi.org/10.64898/2026.09.16.26362994 [This article is a preprint and has not been certified by peer review [](https://www.medrxiv.org/about/FAQ#unrefereed)[what does this mean?](https://www.medrxiv.org/about/FAQ#unrefereed)]. It reports new medical research that has yet to be evaluated and so should _not_ be used to guide clinical practice. Share This Article: Copy [![Twitter logo](https://www.medrxiv.org/sites/all/modules/highwire/highwire/images/twitter.png)](https://www.medrxiv.org/highwire_log/share/twitter?link=http%3A%2F%2Ftwitter.com%2Fshare%3Furl%3Dhttps%253A%2F%2Fwww.medrxiv.org%2Fcontent%2F10.64898%2F2026.09.16.26362994v1%26text%3DThe%2520value%2520of%2520a%2520family%2520history%2520to%2520distinguish%2520monogenic%2520from%2520polygenic%2520amyotrophic%2520lateral%2520sclerosis "Share this on Twitter") [![Facebook logo](https://www.medrxiv.org/sites/all/modules/highwire/highwire/images/fb-blue.png)](https://www.medrxiv.org/highwire_log/share/facebook?link=http%3A%2F%2Fwww.facebook.com%2Fsharer.php%3Fu%3Dhttps%253A%2F%2Fwww.medrxiv.org%2Fcontent%2F10.64898%2F2026.09.16.26362994v1%26t%3DThe%2520value%2520of%2520a%2520family%2520history%2520to%2520distinguish%2520monogenic%2520from%2520polygenic%2520amyotrophic%2520lateral%2520sclerosis "Share on Facebook") [![LinkedIn logo](https://www.medrxiv.org/sites/all/modules/highwire/highwire/images/linkedin-32px.png)](https://www.medrxiv.org/highwire_log/share/linkedin?link=http%3A%2F%2Fwww.linkedin.com%2FshareArticle%3Fmini%3Dtrue%26url%3Dhttps%253A%2F%2Fwww.medrxiv.org%2Fcontent%2F10.64898%2F2026.09.16.26362994v1%26title%3DThe%2520value%2520of%2520a%2520family%2520history%2520to%2520distinguish%2520monogenic%2520from%2520polygenic%2520amyotrophic%2520lateral%2520sclerosis%26summary%3D%26source%3DmedRxiv "Publish this post to LinkedIn") [![Mendeley logo](https://www.medrxiv.org/sites/all/modules/highwire/highwire/images/mendeley.png)](https://www.medrxiv.org/highwire_log/share/mendeley?link=http%3A%2F%2Fwww.mendeley.com%2Fimport%2F%3Furl%3Dhttps%253A%2F%2Fwww.medrxiv.org%2Fcontent%2F10.64898%2F2026.09.16.26362994v1%26title%3DThe%2520value%2520of%2520a%2520family%2520history%2520to%2520distinguish%2520monogenic%2520from%2520polygenic%2520amyotrophic%2520lateral%2520sclerosis "Share on Mendeley") [ Citation Tools](https://www.medrxiv.org/ "Citation Tools") [ Get QR code](https://connect.medrxiv.org/qr/2026.09.16.26362994) Reviews and Context 0 Comment 0 TRIP Peer Reviews 0 Community Reviews 0 Automated Services 0 Blogs/Media 0 Author Videos **Subject Areas** [**All Articles**](https://www.medrxiv.org/content/early/recent) * [Addiction Medicine](https://www.medrxiv.org/collection/addiction-medicine) (619) * [Allergy and Immunology](https://www.medrxiv.org/collection/allergy-and-immunology) (903) * [Anesthesia](https://www.medrxiv.org/collection/anesthesia) (335) * [Cardiovascular Medicine](https://www.medrxiv.org/collection/cardiovascular-medicine) (4834) * [Dentistry and Oral Medicine](https://www.medrxiv.org/collection/dentistry-and-oral-medicine) (479) * [Dermatology](https://www.medrxiv.org/collection/dermatology) (419) * [Emergency Medicine](https://www.medrxiv.org/collection/emergency-medicine) (651) * [Endocrinology (including Diabetes Mellitus and Metabolic Disease)](https://www.medrxiv.org/collection/endocrinology-including-diabetes-mellitus-and-metabolic-disease) (1633) * [Epidemiology](https://www.medrxiv.org/collection/epidemiology) (15981) * [Forensic Medicine](https://www.medrxiv.org/collection/forensic-medicine) (33) * [Gastroenterology](https://www.medrxiv.org/collection/gastroenterology) (1206) * [Genetic and Genomic Medicine](https://www.medrxiv.org/collection/genetic-and-genomic-medicine) (7069) * [Geriatric Medicine](https://www.medrxiv.org/collection/geriatric-medicine) (734) * [Health Economics](https://www.medrxiv.org/collection/health-economics) (1067) * [Health Informatics](https://www.medrxiv.org/collection/health-informatics) (5070) * [Health Policy](https://www.medrxiv.org/collection/health-policy) (1438) * [Health Systems and Quality Improvement](https://www.medrxiv.org/collection/health-systems-and-quality-improvement) (1776) * [Hematology](https://www.medrxiv.org/collection/hematology) (587) * [HIV/AIDS](https://www.medrxiv.org/collection/hiv-aids) (1347) * [Infectious Diseases (except HIV/AIDS)](https://www.medrxiv.org/collection/infectious_diseases) (16312) * [Intensive Care and Critical Care Medicine](https://www.medrxiv.org/collection/intensive-care-and-critical-care-medicine) (1177) * [Medical Education](https://www.medrxiv.org/collection/medical-education) (673) * [Medical Ethics](https://www.medrxiv.org/collection/medical-ethics) (155) * [Nephrology](https://www.medrxiv.org/collection/nephrology) (727) * [Neurology](https://www.medrxiv.org/collection/neurology) (7306) * [Nursing](https://www.medrxiv.org/collection/nursing) (370) * [Nutrition](https://www.medrxiv.org/collection/nutrition) (1087) * [Obstetrics and Gynecology](https://www.medrxiv.org/collection/obstetrics-and-gynecology) (1244) * [Occupational and Environmental Health](https://www.medrxiv.org/collection/occupational-and-environmental-health) (1007) * [Oncology](https://www.medrxiv.org/collection/oncology) (3622) * [Ophthalmology](https://www.medrxiv.org/collection/ophthalmology) (1058) * [Orthopedics](https://www.medrxiv.org/collection/orthopedics) (398) * [Otolaryngology](https://www.medrxiv.org/collection/otolaryngology) (458) * [Pain Medicine](https://www.medrxiv.org/collection/pain-medicine) (476) * [Palliative Medicine](https://www.medrxiv.org/collection/palliative-medicine) (140) * [Pathology](https://www.medrxiv.org/collection/pathology) (709) * [Pediatrics](https://www.medrxiv.org/collection/pediatrics) (1805) * [Pharmacology and Therapeutics](https://www.medrxiv.org/collection/pharmacology-and-therapeutics) (739) * [Primary Care Research](https://www.medrxiv.org/collection/primary-care-research) (769) * [Psychiatry and Clinical Psychology](https://www.medrxiv.org/collection/psychiatry-and-clinical-psychology) (5923) * [Public and Global Health](https://www.medrxiv.org/collection/public-and-global-health) (9778) * [Radiology and Imaging](https://www.medrxiv.org/collection/radiology-and-imaging) (2436) * [Rehabilitation Medicine and Physical Therapy](https://www.medrxiv.org/collection/rehabilitation-medicine-and-physical-therapy) (1456) * [Respiratory Medicine](https://www.medrxiv.org/collection/respiratory-medicine) (1250) * [Rheumatology](https://www.medrxiv.org/collection/rheumatology) (643) * [Sexual and Reproductive Health](https://www.medrxiv.org/collection/sexual-and-reproductive-health) (773) * [Sports Medicine](https://www.medrxiv.org/collection/sports-medicine) (582) * [Surgery](https://www.medrxiv.org/collection/surgery) (783) * [Toxicology](https://www.medrxiv.org/collection/toxicology) (107) * [Transplantation](https://www.medrxiv.org/collection/transplantation) (306) * [Urology](https://www.medrxiv.org/collection/urology) (293) Evaluation/discussion of this paper x Comments 0TRiP 0Community 0Automated 0Blogs/Media 0Video 0 Comments medRxiv aims to provide a venue for anyone to comment on a medRxiv preprint. Comments are moderated for offensive or irrelevant content (this can take ~24 h). Please avoid duplicate submissions. The content of a comment is not endorsed by medRxiv. medRxiv is now using a new commenting interface powered by Hypothes.is. All comments previously submitted via the legacy platform (Disqus) have been transferred to the new platform using the medRxiv_admin account. Please read our [commenting guide](https://connect.biorxiv.org/news/2022/03/21/commenting_on_preprints) for more information. Share this comments tab (click to copy link)Copied! TRiP medRxiv partners with journals and review services to enable posting of peer reviews and editorial decisions related to preprints they are evaluating. Reviews are posted with the consent of the authors. TRiP reviews are part of a peer review pilot project in which participating organizations post peer reviews of manuscripts they are evaluating _There is no TRiP material for this paper._ Community Reviews medRxiv aims to inform readers about online discussion of this preprint occurring elsewhere. The content at the links below is not endorsed by either medRxiv or the preprint's authors. Community reviews for this article: _There are no c
## Related Clinical Research

- [Orexin agonist ALKS 7290 shows ADHD symptom improvement in early Phase 1 trial](https://medichelpline.com/clinical-feed/stat-news-0-stat-alkermes-orexin-agonist-shows-potential-to-treat-adhd-in-early-stage-trial.md)
- [Kennedy launches ARPA-H initiative to accelerate autism diagnoses and research](https://medichelpline.com/clinical-feed/stat-news-0-kennedy-announces-new-effort-to-speed-up-autism-diagnoses.md)
- [Carbon monoxide exposure may explain lower Parkinson's risk linked to smoking](https://medichelpline.com/clinical-feed/medical-news-today-0-why-smokers-may-have-a-lower-parkinson-s-risk-it-s-not-the-nicotine.md)
- [Memory decline may begin in middle age due to hippocampal changes, study finds](https://medichelpline.com/clinical-feed/medical-news-today-0-memory-decline-may-begin-as-early-as-middle-age-a-new-study-suggests.md)
- [Dynamic Clinical States in the First 72 Hours After Acute Stroke in ICU](https://medichelpline.com/clinical-feed/medrxiv-5-dynamic-clinical-states-and-transitions-during-the-first-72-hours-of-intensive.md)

## Navigation
- [← Back to Neurology Feed](https://medichelpline.com/clinical-feed/neurology.md)
- [← All Clinical Specialties](https://medichelpline.com/clinical-feed.md)
## Medical & Regulatory Disclaimer

> [!CAUTION]
> MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations.
> Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.